Company / Accounts Receivable
UTAH MEDICAL PRODUCTS INC Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$3.5M
FY2025
5-year range
$3.4M / $5.1M
FY2021-FY2025
Trend
-14.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has fluctuated over the past 10 years, ranging from $3M in FY2016 to $5M in FY2022.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of -3.0%.
Improved from $3M to $4M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -11.8%
- 5-Year CAGR
- -3.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -3.0%, indicating a declining trend.
- In FY2025, accounts receivable decreased 14.0% year-over-year.
- Peak accounts receivable was recorded in FY2022.
- Lowest accounts receivable in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 16.69 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.5M | -14.0% |
| FY2024 | $4.1M | +20.7% |
| FY2023 | $3.4M | -33.9% |
| FY2022 | $5.1M | +0.0% |
| FY2021 | $5.1M | +25.0% |
| FY2020 | $4.1M | -13.5% |
| FY2019 | $4.7M | +19.9% |
| FY2018 | $4.0M | +9.2% |
| FY2017 | $3.6M | +12.8% |
| FY2016 | $3.2M | -29.6% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026